Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.
Authors
Dirk Schadendorf
University Hospital Essen, Essen, Germany
Dirk Schadendorf, Georgina V. Long, Jean Jacques Grob, Paul D. Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Matthew Squires, Savina Jaeger, William Powell, Puay Tan, Caroline Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Clinical Trial Registration Number
NCT01597908
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 183)
DOI
10.1200/JCO.2018.36.5_suppl.183
Abstract #
183
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.
First Author: Reinhard Dummer
Poster
2019 ASCO Annual Meeting
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
First Author: Nikhil I. Khushalani
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert